罕见病知识库 RareSeen

Phenylalanine hydroxylase deficiency

ORPHA:708881疾病组中国目录 第1批 · 49暂无中文名

别名

PAH deficiency

近两年的全球研究 72L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-09开放获取
    The success-failure inversion in modern medicine
    Frontiers in public health · DOI · Europe PMC
  • 2026-09开放获取
    Global Trends in Phenylketonuria Treatment Research, 2000-2025: Bibliometric Analysis
    Online journal of public health informatics · DOI · Europe PMC
  • 2026-08开放获取
    The Spanish Uniform Newborn Screening Panel (SUSP): A National Consensus Framework for Harmonized Newborn Screening
    International journal of neonatal screening · DOI · Europe PMC
  • 2026-08
    Bone mineral density in participants with phenylalanine hydroxylase (PAH) deficiency: a report from the PHEFREE rare disorders consortium
    Molecular genetics and metabolism · DOI · Europe PMC
  • 2026-08预印本
    The spectrum of PAH variants and genotype-phenotype correlation in patients with phenylalanine hydroxylase deficiency in Inner Mongolia, China
    · DOI
  • 2026-08开放获取
    Health-related quality of life and its influencing factors in Chinese patients with phenylketonuria
    Frontiers in pediatrics · DOI · Europe PMC
  • 2026-08开放获取
    Characterization of Adult Patients With Neurometabolic Disorders: A Cross-Sectional Study at a Tertiary Neurology Center in Sweden
    JIMD reports · DOI · Europe PMC
  • 2026-07开放获取
    Clinical application value of preconception and prenatal carrier screening in Yinchuan
    Frontiers in genetics · DOI · Europe PMC
  • 2026-07综述开放获取
    A Comprehensive Meta-Analytical Investigation into the Incidence of Neonatal Amino Acid Metabolic Disorders Across China
    International journal of neonatal screening · DOI · Europe PMC
  • 2026-07开放获取
    Analysis of <i>PAH</i> Genetic Variation and Phenotypic Diversity in the PAHvdb
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-07开放获取
    Neonatal genetic sequencing as a first-tier option: a real-world clinical implementation study in Northern China
    Annals of medicine · DOI · Europe PMC
  • 2026-07
    Genotype-phenotype relationships in phenylalanine hydroxylase deficiency: Functional annotation-enhanced analysis of 23,427 individuals
    Genetics in medicine : official journal of the American College of Med · 被引 1 · DOI · Europe PMC
  • 2026-07综述开放获取
    Mapping the Severity of Phenylalanine Hydroxylase Deficiency
    Journal of inherited metabolic disease · 被引 1 · DOI · Europe PMC
  • 2026-06
    Factors affecting the success of follow-up and treatment of adults with phenylketonuria diagnosed by newborn screening
    Journal of pediatric endocrinology & metabolism : JPEM · DOI · Europe PMC
  • 2026-06综述病例报告开放获取
    Inborn errors of immunity in Low German Mennonite communities in Mexico: a case series and narrative literature review
    Frontiers in immunology · 被引 1 · DOI · Europe PMC
  • 2026-06开放获取
    Molecular Genetic and Biochemical Characterization of Hyperphenylalaninemia Based on Expanded Neonatal Screening Data from 2023 to 2024 in the Russian Federation
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-06
    Toward personalized treatment in phenylketonuria: Intra-individual variation of in vivo phenylalanine oxidation using the <sup>13</sup>C-phenylalanine breath test
    Molecular genetics and metabolism · DOI · Europe PMC
  • 2026-06
    A phenylketonuria mouse model exhibits EEG spike-wave discharges: Effects of sleep deprivation and low-Phe diet
    Neurobiology of disease · DOI · Europe PMC
  • 2026-05综述开放获取
    Phenylalanine-tyrosine-catecholamine axis disorders: pathways, molecular diagnosis, therapeutics, and emerging translational monitoring technologies
    Frontiers in molecular biosciences · DOI · Europe PMC
  • 2026-05开放获取
    Concurrent Phenylalanine Hydroxylase-Related Disorder and Celiac: A Rare Co-occurrence With Implications for Clinical Management
    Annals of internal medicine. Clinical cases · DOI · Europe PMC

境外已获批用于本病的药物 5L2

欧盟 2 项、美国 3 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

尚未获批的在研药物(8 项)

这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • 5,6,7,8-Tetrahydrobiopterin欧盟2003-10-02
    Treatment of hyperphenylalaninaemia
    官方记录
  • particles comprised of methacrylic acid based co-polymer, cross-linked欧盟2016-11-18
    Treatment of hyperphenylalaninaemia
    官方记录
  • Escherichia coli, strain Nissle 1917, expressing high affinity phenyla欧盟2023-04-21
    Treatment of hyperphenylalaninaemia
    官方记录
  • 2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-o欧盟2024-05-24
    Treatment of hyperphenylalaninaemia
    官方记录
  • (R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)pip欧盟2024-06-28
    Treatment of hyperphenylalaninaemia
    官方记录
  • adeno-associated virus vector serotype SNY001 containing the human PAH欧盟2025-02-26
    Treatment of hyperphenylalaninaemia
    官方记录
  • Valine, isoleucine and leucine美国1996-01-05
    Treatment of hyperphenylalaninemia
    官方记录
  • Particles comprised ofmethacrylic acid based co-polymer, cross-linked 美国2020-02-27
    Treatment of hyperphenylalaninemia
    官方记录

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 7L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

登记为可入组 4

  • 招募中NCT06687733
    Safety and Efficacy Study of NGGT002 in Adult Patients With Phenylketonuria
    I 期、II 期 · 干预性 · 2024/07/16NGGT (Suzhou) Biotechnology Co., Ltd.
    中国研究中心 2 个:Bengbu、Shanghai
  • 招募中NCT07672756
    A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)
    I 期 · 干预性 · 2025/07/20Chongqing Peg-Bio Biopharm Co., Ltd.
    中国研究中心 1 个:Hefei
  • 招募中NCT07685210
    GenSci144 Tablets Phase I Clinical Trial
    I 期 · 干预性 · 2026/06/22Changchun GeneScience Pharmaceutical Co., Ltd.
    中国研究中心 1 个:Jinan
  • 尚未开始招募NCT07318909
    To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
    早期 I 期 · 干预性 · 2027/12/31Gritgen Therapeutics Co., Ltd.
    中国研究中心 1 个:Hefei
其他状态的试验(3 项)
  • 已完成NCT03864029
    Retrospective Observational Safety Effectiveness With Kuvan in hpA
    观察性 · 2017/10/10BioMarin Pharmaceutical
    中国研究中心 1 个:Chengdu
  • 进行中·不再招募NCT06061614
    Safety and Efficacy Study of NGGT002 in PKU Adult Subjects
    早期 I 期 · 干预性 · 2023/03/30The First Affiliated Hospital of Bengbu Medical University
    中国研究中心 1 个:Bengbu
  • 已完成NCT05948020
    Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria
    早期 I 期 · 干预性 · 2023/09/02Children's Hospital of Fudan University
    中国研究中心 1 个:Shanghai

中国境外的在招试验 35L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

美国16英国5法国5波兰4澳大利亚4德国3加拿大2瑞士2意大利2捷克1日本1荷兰1西班牙1丹麦1另有 3 个国家/地区

CT.gov 报告命中 35 项,此处取回并展示最近的 15 项。

  • 尚未开始招募NCT07802366
    Acceptability and Tolerance Market Research of a Slow Release, Phenylalanine-free Protein Substitute for the Dietary Management of Phenylketonuria
    不适用 · 干预性 · 2026/10/01metaX Institut fuer Diatetik GmbH
    英国
  • 招募中NCT07825883
    The Impact of Frequency of Home Phenylalanine Measurements on Metabolic Control in a Population of Patients With Classic Phenylketonuria
    不适用 · 干预性 · 2026/09/11Michał Kania
    波兰
  • 招募中NCT07551921
    PheCheck™ Validation Study
    观察性 · 2026/08/20Aptatek BioSciences, Inc
    美国
  • 招募中NCT07713758
    A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function
    I 期 · 干预性 · 2026/07/17Otsuka Pharmaceutical Development & Commercialization, Inc.
    美国
  • 尚未开始招募NCT07671859
    PKU Microtablets Case Studies
    不适用 · 干预性 · 2026/07/01Nutricia UK Ltd
    英国
  • 招募中NCT07694440
    A Study of MZE782 in Adults With PKU
    II 期 · 干预性 · 2026/06/23Maze Therapeutics
    美国
  • 招募中NCT07477691
    Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
    IV 期 · 干预性 · 2026/05/29BioMarin Pharmaceutical
    美国
  • 招募中NCT07241234
    A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
    I 期 · 干预性 · 2026/04/17Agios Pharmaceuticals, Inc.
    波兰、美国
  • 招募中NCT07446400
    A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
    I 期 · 干预性 · 2026/03/31Otsuka Pharmaceutical Development & Commercialization, Inc.
    澳大利亚
  • 招募中NCT07484945
    Multiomics Approach in Adult Patients With Phenylketonuria
    观察性 · 2026/03/23University Hospital, Tours
    法国
  • 尚未开始招募NCT07406009
    The Psychosocial Functioning of Adults With Phenylketonuria.
    观察性 · 2026/01/15Central Hospital, Nancy, France
  • 招募中NCT07220265
    Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
    不适用 · 干预性 · 2025/12/19University of Missouri-Columbia
    美国
  • 招募中NCT07698743
    Eating Disorders in Patients With Phenylketonuria
    观察性 · 2025/12/04Central Hospital, Nancy, France
    法国
  • 招募中NCT06971731
    A Study of JNT-517 in Participants With Phenylketonuria (PKU)
    III 期 · 干预性 · 2025/10/20Otsuka Pharmaceutical Development & Commercialization, Inc.
    澳大利亚、加拿大、捷克、法国、德国、日本、荷兰、波兰 等 10 国
  • 招募中NCT07728032
    Impact Of A Phe-Restricted Diet On Gut Health In Children With PKU
    观察性 · 2025/10/01Birmingham Women's and Children's NHS Foundation Trust
    英国

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01;本条目在该版本中无中文名
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)